June 2, 2026 |
Across sessions, panels, and conversations on the ground in Denver, there was a noticeable shift in both mindset and momentum. Many of the themes discussed in previous years are now being actively implemented, with teams moving beyond theory and into execution.

Here are five key takeaways shaping the future of Medical Affairs.
1. Medical Affairs is stepping into a strategic leadership role
Medical Affairs is no longer operating at the margins of strategy. It is increasingly being brought earlier into the development process, co-leading product launches, in some situations functionally leading product launch, and influencing enterprise decision-making.
As Gemma Pfister (Senior Consulting Executive, Inizio Ignite) and Eric Wood (Head of Commercial, Transformation, Inizio Ignite) observed, teams are now “required to translate complex science into enterprise value,” reflecting a fundamental shift in expectations.
There is also a growing emphasis on engaging at a more senior level. Varun Renjen (Partner, Inizio Ignite) highlighted the importance of Medical Affairs leaders being able to “speak the pipeline, the top line and the bottom line,” reinforcing the need for commercial fluency alongside scientific expertise.
This evolution marks a turning point. Medical Affairs is not just supporting strategy, it is helping define it.
2. The shift from activity to impact is accelerating
A consistent theme throughout MAPS was the need to move beyond activity-based metrics and demonstrate real, measurable impact.
Jo Ann Saitta (Head of Data & AI, Inizio Ignite), pointed to the growing focus on “where they are moving the needle on patient impact,” with teams increasingly leveraging real-world data to demonstrate changing behaviors and value.
Importantly, this is not about proving value for the first time. As Eric Wood reflected, “medical has already reached the milestone of proving effectiveness.” The challenge now is to communicate that value more clearly and consistently across the organization.
Dean McAlister (Executive Vice President, Biotech Enterprise Solutions, Inizio Biotech) captured this shift powerfully, highlighting the importance of bringing data to life through storytelling: “we move it from hands and feet to the hearts and minds of the people involved.”
The implication is clear. Demonstrating impact is no longer optional. It is a core capability for Medical Affairs teams.
Read the full blog here.
This content was provided by Inizio
Latest Content from Inizio
How rare are rare diseases in China? Download this infographic to find out more and how we can offer guidance for pharma companies to consider.
Living with COPD 2023
How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics.
With over 20 years' experience in the industry, Research Partnership Senior Director and market research veteran Andrew Stokes has been appointed Chief Commercial Officer.
Find out how we provided a more holistic understanding of brand equity and a forward indication of potential market share using our advanced analytics solution, Equity AI.
In a recent interview for PME Magazine, Roy Rogers shows how to navigate the busy omnichannel communication lanes to make the best of digital.
Research Partnership is delighted to announce the appointments of Sue Wild as President, US Pharma in the US and Tom Donnelly as a Director in the US MedTech division.
Find out how we helped our client to obtain an intuitive and actionable segmentation in order to drive market shaping activities ahead of their product launch aimed at the treatment...
Tania Rodrigues investigates the market access and commercialization potential for manufacturers of CAR-T therapies in the latest issue of pharmaphorum's Deep Dive.
We are delighted to announce Research Partnership were announced the winners in the ‘Creative Fieldwork Team of the Year’ category at the BHBIA’s Best of Business Intelligence (BOBI) Awards.
